Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial

BACKGROUND: Vaccines against COVID-19 are needed to overcome challenges associated with mitigating the global pandemic. We report the safety and immunogenicity of V590, a live recombinant vesicular stomatitis virus-based COVID-19 vaccine candidate. METHODS: In this placebo-controlled, double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Robbins, Jonathan A., Tait, Dereck, Huang, Qinlei, Dubey, Sheri, Crumley, Tami, Cote, Josee, Luk, Julie, Sachs, Jeffrey R., Rutkowski, Kathryn, Park, Harriet, Schwab, Robert, Howitt, William Joseph, Rondon, Juan Carlos, Hernandez-Illas, Martha, O'Reilly, Terry, Smith, William, Simon, Jakub, Hardalo, Cathy, Zhao, Xuemei, Wnek, Richard, Cope, Alethea, Lai, Eseng, Annunziato, Paula, Guris, Dalya, Stoch, S. Aubrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259069/
https://www.ncbi.nlm.nih.gov/pubmed/35809371
http://dx.doi.org/10.1016/j.ebiom.2022.104138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259069/
https://www.ncbi.nlm.nih.gov/pubmed/35809371
http://dx.doi.org/10.1016/j.ebiom.2022.104138

Ejemplares similares